Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes
Vitor F. Martins, Samuel A. LaBarge, Alexandra Stanley, Kristoffer Svensson, Chao-Wei Hung, Omer Keinan, Theodore P. Ciaraldi, Dion Banoian, Ji E. Park, Christina Ha, Byron Hetrick, Gretchen A. Meyer, Andrew Philp, Larry L. David, Robert R. Henry, Joseph E. Aslan, Alan R. Saltiel, Carrie. E. McCurdy, Simon Schenk
Vitor F. Martins, Samuel A. LaBarge, Alexandra Stanley, Kristoffer Svensson, Chao-Wei Hung, Omer Keinan, Theodore P. Ciaraldi, Dion Banoian, Ji E. Park, Christina Ha, Byron Hetrick, Gretchen A. Meyer, Andrew Philp, Larry L. David, Robert R. Henry, Joseph E. Aslan, Alan R. Saltiel, Carrie. E. McCurdy, Simon Schenk
View: Text | PDF
Research Article Endocrinology Muscle biology

p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes

  • Text
  • PDF
Abstract

While current thinking posits that insulin signaling to glucose transporter 4 (GLUT4) exocytic translocation and glucose uptake in skeletal muscle and adipocytes is controlled by phosphorylation-based signaling, many proteins in this pathway are acetylated on lysine residues. However, the importance of acetylation and lysine acetyltransferases to insulin-stimulated glucose uptake is incompletely defined. Here, we demonstrate that combined loss of the acetyltransferases E1A binding protein p300 (p300) and cAMP response element binding protein binding protein (CBP) in mouse skeletal muscle caused a complete loss of insulin-stimulated glucose uptake. Similarly, brief (i.e., 1 hour) pharmacological inhibition of p300/CBP acetyltransferase activity recapitulated this phenotype in human and rodent myotubes, 3T3-L1 adipocytes, and mouse muscle. Mechanistically, these effects were due to p300/CBP-mediated regulation of GLUT4 exocytic translocation and occurred downstream of Akt signaling. Taken together, we highlight a fundamental role for acetylation and p300/CBP in the direct regulation of insulin-stimulated glucose transport in skeletal muscle and adipocytes.

Authors

Vitor F. Martins, Samuel A. LaBarge, Alexandra Stanley, Kristoffer Svensson, Chao-Wei Hung, Omer Keinan, Theodore P. Ciaraldi, Dion Banoian, Ji E. Park, Christina Ha, Byron Hetrick, Gretchen A. Meyer, Andrew Philp, Larry L. David, Robert R. Henry, Joseph E. Aslan, Alan R. Saltiel, Carrie. E. McCurdy, Simon Schenk

×

Figure 1

p300 and CBP are required for skeletal muscle insulin-stimulated glucose uptake.

Options: View larger image (or click on image) Download as PowerPoint
p300 and CBP are required for skeletal muscle insulin-stimulated glucose...
Male PCKO mice were assessed at 1 (D1), 3 (D3), or 5 (D5) days after initiating tamoxifen. (A–C) Blood glucose concentrations and area under the curve (AUC; inset) for male PCKO mice at D1, D3, and D5 during an oral glucose tolerance test (OGTT; 2 g/kg); D1: WT/PCKO n = 5/9, D3: WT/PCKO n = 6/10, D5: WT/PCKO n = 6/11. *, P < 0.05 2-way ANOVA repeated measures, PCKO versus WT within a time point for OGTT, and *, P < 0.05 t test for AUC. (D–F) Basal 2-deoxy-glucose uptake (2DOGU), insulin (0.36 nmol/L) 2DOGU, and (G–I) insulin-stimulated 2DOGU (I-Stim.; calculated as insulin 2DOGU – basal 2DOGU) in isolated soleus and extensor digitorum longus (EDL) muscles from male WT and PCKO mice at D1, D3, and D5; D1: WT/PCKO n = 11/10, D3: WT/PCKO n = 6/7, D5: WT/PCKO n = 7/10. *, P < 0.05 2-way ANOVA with Sidak’s multiple comparison versus basal within genotype (D–F) and #, P < 0.05 versus WT within basal or insulin (G–I). *, P < 0.05 t test for I-Stim. ^, P > 0.05 1-sample t test versus “0”. (J) Representative images for phospho-AktT308 (pAktT308), phospho-AktS473 (pAktS473), total Akt, phospho-GSK3bS9 (pGSK3bS9), and total GSK3b in basal and insulin-stimulated (- and +, respectively) EDL muscles from WT and PCKO mice at D1, D3, and D5. Quantification of (K) pAktT308, (L) pAktS473, and (M) pGSK3bS9 compared with total respective protein abundance in the EDL muscle; WT/D1/D3/D5 n = 15/5/6/11. Values are presented relative to WT-insulin. *, P < 0.05 2-way ANOVA, main effect of insulin. Data reported as mean ± SEM. For Western blots, there were no significant differences between WT mice at the different time points (D1, D3, and D5); therefore WT data were collapsed.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts